422 related articles for article (PubMed ID: 37679807)
1. Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA).
Ali JH; Walter M
Cancer Cell Int; 2023 Sep; 23(1):197. PubMed ID: 37679807
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targeting of Telomerase.
Jäger K; Walter M
Genes (Basel); 2016 Jul; 7(7):. PubMed ID: 27455328
[TBL] [Abstract][Full Text] [Related]
3. Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.
Gao J; Pickett HA
Nat Rev Cancer; 2022 Sep; 22(9):515-532. PubMed ID: 35790854
[TBL] [Abstract][Full Text] [Related]
4. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
5. Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof.
Claude E; Decottignies A
Curr Opin Genet Dev; 2020 Feb; 60():1-8. PubMed ID: 32114293
[TBL] [Abstract][Full Text] [Related]
6. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
7. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
8. Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
De Vitis M; Berardinelli F; Sgura A
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463031
[TBL] [Abstract][Full Text] [Related]
9. Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies.
Babizhayev MA; Yegorov YE
J Biomed Mater Res A; 2015 Dec; 103(12):3993-4023. PubMed ID: 26034007
[TBL] [Abstract][Full Text] [Related]
10. Alternative lengthening of telomeres (ALT) and chromatin: is there a connection?
Nittis T; Guittat L; Stewart SA
Biochimie; 2008 Jan; 90(1):5-12. PubMed ID: 17935854
[TBL] [Abstract][Full Text] [Related]
11. Switch telomerase to ALT mechanism by inducing telomeric DNA damages and dysfunction of ATRX and DAXX.
Hu Y; Shi G; Zhang L; Li F; Jiang Y; Jiang S; Ma W; Zhao Y; Songyang Z; Huang J
Sci Rep; 2016 Aug; 6():32280. PubMed ID: 27578458
[TBL] [Abstract][Full Text] [Related]
12. Treating Cancer by Targeting Telomeres and Telomerase.
Ivancich M; Schrank Z; Wojdyla L; Leviskas B; Kuckovic A; Sanjali A; Puri N
Antioxidants (Basel); 2017 Feb; 6(1):. PubMed ID: 28218725
[TBL] [Abstract][Full Text] [Related]
13. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT.
Cerone MA; Autexier C; Londoño-Vallejo JA; Bacchetti S
Oncogene; 2005 Nov; 24(53):7893-901. PubMed ID: 16116482
[TBL] [Abstract][Full Text] [Related]
14. Potential clinical treatment prospects behind the molecular mechanism of alternative lengthening of telomeres (ALT).
Sun H; Chen G; Guo B; Lv S; Yuan G
J Cancer; 2023; 14(3):417-433. PubMed ID: 36860927
[TBL] [Abstract][Full Text] [Related]
15. Oligonucleotides and G-quadruplex stabilizers: targeting telomeres and telomerase in cancer therapy.
Crees Z; Girard J; Rios Z; Botting GM; Harrington K; Shearrow C; Wojdyla L; Stone AL; Uppada SB; Devito JT; Puri N
Curr Pharm Des; 2014; 20(41):6422-37. PubMed ID: 24975605
[TBL] [Abstract][Full Text] [Related]
16. Telomerase-independent paths to immortality in predictable cancer subtypes.
Durant ST
J Cancer; 2012; 3():67-82. PubMed ID: 22315652
[TBL] [Abstract][Full Text] [Related]
17. Telomere maintenance in sarcomas.
Johnson JE; Broccoli D
Curr Opin Oncol; 2007 Jul; 19(4):377-82. PubMed ID: 17545803
[TBL] [Abstract][Full Text] [Related]
18. Alternative lengthening of telomeres: from molecular mechanisms to therapeutic outlooks.
Zhang JM; Zou L
Cell Biosci; 2020; 10():30. PubMed ID: 32175073
[TBL] [Abstract][Full Text] [Related]
19. Alternative Lengthening of Telomeres in the Budding Yeast
Cohn M; Andersson AK; Mateo RQ; Möller MC
G3 (Bethesda); 2019 Oct; 9(10):3345-3358. PubMed ID: 31427453
[TBL] [Abstract][Full Text] [Related]
20. Alternative Lengthening of Telomeres in Pediatric Cancer: Mechanisms to Therapies.
Kent T; Gracias D; Shepherd S; Clynes D
Front Oncol; 2019; 9():1518. PubMed ID: 32039009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
